MicroRNA

Exosome Diagnostics, Therapeutics and Research Tools Global Market Research 2024-2028: Commercial Opportunities and Trends, Patent Analysis and Sustainability Trends, Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Freitag, Mai 24, 2024
General Health, Medical Devices, Health, Science, Research, ESG, Exosome, Bio-Techne, Prevalence, Conditional sentence, Therapy, Safety, Traction, Growth, Dicarboxylic acid, Biomarker, MicroRNA, Liquid biopsy, Medical device

The "Exosome Diagnostics, Therapeutics and Research Tools: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Exosome Diagnostics, Therapeutics and Research Tools: Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • This analysis provides a comprehensive estimate of the current market size and revenue growth prospects, alongside a detailed market share analysis based on product, application, end user, and region.
  • Key market drivers include the growing application of exosome diagnostics in personalized medicine and the rising prevalence of chronic diseases.
  • These developments are crucial in facilitating new commercial opportunities in diagnostics, therapeutics, and research tools markets.

Radar Therapeutics Raises $13.4M in Seed Funding to Develop Smart Programmable Medicines Using Molecular RNA Sensors

Retrieved on: 
Donnerstag, Mai 23, 2024
Hardware, FDA, Data Management, Other Health, Technology, Pharmaceutical, Oncology, Genetics, Clinical Trials, Science, Biotechnology, Software, Other Science, Health, Research, Radar, Chemical engineering, Doctor of Philosophy, Biology, Data, Eli Lilly and Company, ADAR, MicroRNA, RNA, Stanford University, Messenger, Therapy, Safety, MIT, Vaccine, Nature Biotechnology, Chemical substance, Gene, Entrepreneurship, CSO, Medicine, Associate, RNA editing, Multimedia, RADAR, Enzyme

Radar Therapeutics , a biotech company developing smart programmable medicines, today announced the completion of an oversubscribed $13.4 million in seed financing led by NfX Bio.

Key Points: 
  • Radar Therapeutics , a biotech company developing smart programmable medicines, today announced the completion of an oversubscribed $13.4 million in seed financing led by NfX Bio.
  • View the full release here: https://www.businesswire.com/news/home/20240523395742/en/
    Radar Therapeutics founders Sophia Lugo, CEO and Eerik Kaseniit, PhD, CSO & President.
  • Photo credit: Radar Therapeutics
    Current genetic medicines, including mRNA therapeutics, are not targeted and typically rely on cell surface proteins to confer targeting, which limits application.
  • “Like a safety switch, our payload is always off, and only gets turned on in the right cell,” said Sophia Lugo, CEO & Co-Founder, Radar Therapeutics.

Encoded Therapeutics Presents Preclinical Data Across its Gene Therapy Portfolio at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Dienstag, Mai 7, 2024
Biotechnology, Neurology, Health, Genetics, Pharmaceutical, DRG, SCN9A, Seizure, Risk, Angelman syndrome, Locomotion, UBE3A, Human, Neurodevelopmental disorder, Abstract, Code, AAV, Epilepsy, Ataxia, CNS, GABAergic, Disease, Incidence, IPSC, Spinal cord, MAPT, Intellectual disability, Central nervous system, DSM-IV codes, Neuron, NHP, Therapy, Gene, MicroRNA, Vaccine

“We are thrilled to share multiple advancements across our portfolio of precision genetic medicines, showcasing substantial progress across various fronts.

Key Points: 
  • “We are thrilled to share multiple advancements across our portfolio of precision genetic medicines, showcasing substantial progress across various fronts.
  • These data underscore our platform’s potential to deliver precision therapies for a range of CNS diseases,” said Stephanie Tagliatela, Chief Scientific Officer at Encoded.
  • Encoded’s vector engineering platform has enabled the development of GABA-selective AAV-mediated gene therapies designed to potentiate GABAergic neurotransmission and modulate the circuit dysfunction underlying refractory epilepsies.
  • These data support further development of our candidate gene therapy for the treatment for refractory epilepsies.

Alcyone Therapeutics Announces Appointment of Dr. Norbert Riedel as Chairman of the Board and Dr. Kathrin Meyer as Chief Scientific Officer and Head of Research & Development

Retrieved on: 
Mittwoch, Mai 8, 2024
Doctor of Philosophy, University, MicroRNA, Gene therapy, Hospital, Central nervous system disease, Rett syndrome, Innovation, Jazz Pharmaceuticals, Research, Ohio State University, History, CNS, Baxter International, Therapy, Batten disease, Patient, Acquisition, Gene expression, Nationwide Children's Hospital, Central nervous system, Health, SMARD1, Growth, Medical device

LOWELL, Mass., May 8, 2024 /PRNewswire/ -- Alcyone Therapeutics, a clinical-stage biotechnology company pioneering next-generation precision genetic therapies for complex neurological conditions, today announces appointments of Norbert Riedel, Ph.D., a skilled and experienced biopharmaceutical executive, as the Chairman of its Board of Directors, and Kathrin Meyer, Ph.D., a leader in development and clinical translation of genetic therapies for the central nervous system (CNS), as Alcyone's new Chief Scientific Officer and Head of R&D.

Key Points: 
  • "I am delighted and honored to join the board of Alcyone Therapeutics," said Dr. Riedel.
  • I am very excited about the programs we have in development to address the significant unmet patient needs in several neurological indications."
  • "Developing neurological genetic therapies demands both a highly precise biological mechanism of action and effective delivery to the central nervous system.
  • Dr. Kathrin Meyer is a pioneer in the research and clinical development of novel therapies for the CNS.

Global RNAi Therapeutics Market Insights & Forecasts with Potential Impact of COVID-19 2024-2028 Featuring Sanofi, Alnylam, Arrowhead, Arbutus Biopharma, Benitec Biopharma, Sirnaomics - ResearchAndMarkets.com

Retrieved on: 
Freitag, Mai 3, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Molecule, MicroRNA, Investment, RNA interference, Hospital, Infection, RNA, Research, Liver, HTS, Therapy, DSM-IV codes, COVID-19, Prevalence, Row

The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
  • The global RNAi therapeutics market is expected to record a value of US$1.39 billion in 2028, progressing at a CAGR of 9.98%, over the period 2024-2028.
  • Whereas, the global RNAi therapeutics market is split into research & academic laboratories and hospitals & diagnostic laboratories, in terms of end-user.
  • The report provides a comprehensive analysis of the global RNAi therapeutics market segmented on the basis of molecule type, application, end-user and region, with potential impact of COVID-19.

microRNA (miRNA) Global Strategic Research Report 2024-2030: North America Dominates the $840+ Million Market, Asia-Pacific to Witness Steady Growth - ResearchAndMarkets.com

Retrieved on: 
Dienstag, April 23, 2024
Health, Other Health, MicroRNA, Cardiovascular disease, Stroke, Incidence, Polymerase chain reaction, Growth, Research, PCR, Mortality, Market, Government, Pet industry

The "microRNA (miRNA) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "microRNA (miRNA) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • In 2023, the global market for microRNA (miRNA) is characterized by the market share of key competitors, reflecting their varied presence categorized as strong/active/niche/trivial players.
  • The outlook for the miRNA market is promising, with rapid growth anticipated, particularly in the disease diagnostics segment.
  • The U.S. Market is Estimated at $135.7 Million, While China is Forecast to Grow at 16.2% CAGR
    While North America currently dominates the global miRNA market, steady growth is forecasted in the Asia-Pacific region.

Encoded Therapeutics Provides Pipeline Updates From Its Vector Engineering Platform Ahead of Four Preclinical Presentations at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Dienstag, April 23, 2024
Biotechnology, Genetics, Health, Factorization of polynomials, Lennox–Gastaut syndrome, Brain, DRG, DSM-IV codes, SCN9A, Dorsal root ganglion, Dravet syndrome, ETF, Central nervous system disease, Gene silencing, LGS, Transgene, Neuroscience, Abstract, Code, CNS, GABAergic, Engineering, Res, Interneuron, MAPT, Angelman syndrome, Neuropathic pain, Central nervous system, Therapy, MicroRNA, Vaccine

Presentations will highlight progress of preclinical programs for Angelman syndrome, Lennox-Gastaut syndrome (LGS), STXBP1-related disorders (STXBP1-RD), Alzheimer’s disease (MAPT) and neuropathic pain (SCN9A), together with innovations in the company’s vector engineering platform.

Key Points: 
  • Presentations will highlight progress of preclinical programs for Angelman syndrome, Lennox-Gastaut syndrome (LGS), STXBP1-related disorders (STXBP1-RD), Alzheimer’s disease (MAPT) and neuropathic pain (SCN9A), together with innovations in the company’s vector engineering platform.
  • “Our ASGCT presentations showcase the depth and versatility of our vector engineering platform to develop highly specific precision therapies for CNS disorders with high unmet need,” said Stephanie Tagliatela, Chief Scientific Officer at Encoded.
  • “Combining our novel regulatory elements and transgenes provides control of expression in target cells, potentially enabling treatment of devastating, intractable diseases.
  • Engineered transgenes include transcription factors (eTFs) that upregulate the expression of endogenous genes as well miRNA sequences derived from Encoded’s miRNA discovery platform.

Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Donnerstag, März 28, 2024
Research, Ovarian cancer, California Department, Conference call, Conference, Development, MicroRNA, Artificiality, Patient, Travel, Cancer, Information technology, AUP, Society, Gynaecology, AACR, Poster, Medicare, Marketing, CMS, Human resources, Federal, Medi-Cal, Cryptocurrency

AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements.
  • Aspira will be reimbursed at a rate of $897 for all Ova1Plus tests processed for Medi-Cal patients meeting applicable coverage requirements.
  • Gross profit margin was 57.5% for the year ended December 31, 2023, compared to 52.8% for the year ended December 31, 2022.
  • Subsequent to the end of the quarter, Aspira raised $5.5 million in gross proceeds in a registered direct offering and concurrent private placement.

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Montag, April 8, 2024
Science, Biotechnology, Research, Oncology, Health, Health Technology, Genetics, Clinical Trials, Breast cancer, Survival, Immunotherapy, Health equity, Patient, Lung, City, National Cancer Institute, AGAF, Breast, MicroRNA, Pancreatic cancer, Lymphocyte, Clinical trial, Neoplasm, Therapy, Cancer, Exosome, Plasma, Colorectal cancer, Risk, Experiment, DNA, Virus, Translational Genomics Research Institute, Memory, Treatment, Cholangiocarcinoma, Pathology, Liquid biopsy, Microbiome, Recurrence, Irell & Manella, Disease, Intelligence, Molecular diagnostics, Overalls, AACR, TILS, Pancreas, Prognosis, Beckman Research Institute, Biomarker, Abdomen, Biology, Abstract, Bangladesh Technical Education Board, Data, Blood, Medical imaging

“City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.

Key Points: 
  • “City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.
  • “Cancer is complex and the breadth and diversity of research this year further underscores the talent, scientific rigor and curiosity at City of Hope,” Van den Brink added.
  • But those diagnosed when the cancer is contained to the pancreas have a 44.3% relative survival rate after five years.
  • Scientists with Translational Genomics Research Institute, part of City of Hope, also contributed to the study.

National Geographic Magazine Showcases NanoString’s Spatial Biology Technology to Examine Cell Death in Alzheimer’s Disease

Retrieved on: 
Mittwoch, März 27, 2024
Seniors, Nanotechnology, Research, Software, Medical Devices, Hardware, Consumer, Genetics, Professional Services, Science, Technology, Clinical Trials, Publishing, Data Analytics, Biotechnology, Health, Communications, Health Technology, National Geographic, MicroRNA, Brain, Gene, Myenteric plexus, Gene expression, NanoString Technologies, Cell, Disease, Memory, Alzheimer's disease, Tau, Risk, Hippocampus, Inflammation, Patient, RNA, News, Federal republic, Protein, Biology, Proteomics, Publication, OTC, Ecosystem, Multimedia, SMI, Ageing

When blue, magenta, and green all appear in a cell, especially a large cell, that's evidence it is a zombie cell.

Key Points: 
  • When blue, magenta, and green all appear in a cell, especially a large cell, that's evidence it is a zombie cell.
  • (Graphic: NanoString)
    A special-interest magazine from National Geographic called Anti-Inflammation, available on newsstands this week, spotlights the role of inflammation on health and disease.
  • NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology.
  • The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere.